Lung Cancer
Conditions
Interventions
Treatment Group:Gefitinib plus pemetrexed and bevacizumab
Control Group:Gefitinib plus pemetrexed and carboplatin
Sponsors
Shandong Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged >= 18 and <= 75; 2. Patients whose life expectancy exceeds 3 months; 3. Patients with at least one measurable focus other than brain; 4. NSCLC patients with stage IV non squamous cells confirmed by histology and living cytology; 5. ECOG score 0-1; 6. Never accept any systemic anti-tumor treatment; 7. EGFR mutation was positive (including 19del, L858R, g719a, g719c, G719S, l861q); 8. No brain metastasis, or with no symptomatic brain metastases, or symptomatic brain metastases after treatment was stable.
Exclusion criteria
Exclusion criteria: 1. Patients with mixed NSCLC with squamous cell morphology; 2. Mixed lung cancer patients with small cell carcinoma, neuroendocrine carcinoma and sarcoma; 3. EGFR non sensitive mutation or EGFR non mutation patients; 4. Patients with meningioma, meningeal metastases, or unstable brain metastases; 5. Patients who have received chemotherapy or EGFR-TKIs in the past; patients who have received adjuvant or neoadjuvant treatment and the last treatment to recurrence time <= 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR;DCR;TTR;DOR;Adverse events; | — |
Countries
China
Contacts
Public ContactLiu Jie
Shandong Cancer Hospital
Outcome results
None listed